Other Consolidated Financial Statement Detail Other Income (Expense), Net Components of other income (expense), net, are summarized as follows: | | | | | | | | | | | | | | | | | | For the Three Months
Ended September 30, | | For the Nine Months
Ended September 30, | (In millions) | 2012 | | 2011 | | 2012 | | 2011 | Interest income | $ | 5.9 |
| | $ | 5.3 |
| | $ | 22.6 |
| | $ | 13.3 |
| Interest expense | (8.7 | ) | | (7.9 | ) | | (23.1 | ) | | (25.5 | ) | Impairments of investments | (3.5 | ) | | (0.8 | ) | | (4.8 | ) | | (7.6 | ) | Gain (loss) on investments, net | 1.3 |
| | (0.1 | ) | | 15.6 |
| | 15.4 |
| Foreign exchange gains (losses), net | 0.1 |
| | (4.8 | ) | | 0.2 |
| | (5.8 | ) | Other, net | 0.4 |
| | 0.6 |
| | 3.1 |
| | 0.7 |
| Total other income (expense), net | $ | (4.5 | ) | | $ | (7.7 | ) | | $ | 13.5 |
| | $ | (9.5 | ) |
Accrued Expenses and Other Accrued expenses and other consists of the following: | | | | | | | | | (In millions) | As of
September 30,
2012 | | As of
December 31,
2011 | Employee compensation and benefits | $ | 198.7 |
| | $ | 176.3 |
| Revenue-related rebates | 160.2 |
| | 115.0 |
| Deferred revenue | 140.6 |
| | 69.6 |
| Collaboration expenses | 46.6 |
| | 44.2 |
| Clinical development expenses | 52.9 |
| | 40.8 |
| Royalties and licensing fees | 45.3 |
| | 47.4 |
| Current portion of contingent consideration obligations | 21.3 |
| | 10.8 |
| Other | 200.6 |
| | 173.1 |
| Total accrued expenses and other | $ | 866.2 |
| | $ | 677.2 |
|
|